Twelve Sites, Twelve Opinions

A hospital network negotiates a single supply contract for marrow needles. Twelve sites are covered. Six months later, the formulary reports that one site consumes almost exclusively 13G, another 15G, a third orders 18G in volume and 11G only on request. Prices are unified; practice is not.

Consolidation of this kind usually focuses on price and logistics. It rarely addresses the decision that determines whether the standardised product performs: which size each site actually needs, and on what basis that need was established. Without a size standard, a network buys the same catalogue and uses it twelve different ways.

Why Size Standardisation Is a Clinical Exercise

Size determines the mechanical interface between instrument and patient. Two sites using different gauges for the same indication are not making a stylistic choice; they are producing different specimens, different complication profiles, and different procedure durations.

Standardisation therefore has two distinct goals. The first is supply efficiency: fewer sizes, deeper stock, simpler tendering, and predictable forecasting. The second is clinical consistency: the same indication producing the same specimen quality and the same patient experience regardless of which site the patient attends.

The two goals pull in different directions. Aggressive SKU reduction achieves efficiency at the cost of fit; leaving every site to order freely achieves fit at the cost of efficiency. The workable position lies in a core matrix held network-wide plus a small, justified allowance for local variation.

The Technical Basis for a Network Matrix

A defensible matrix is built from anatomy and indication rather than from preference.

Anatomy sets the outer bounds. Posterior iliac access in adults with normal habitus typically sits in the 13G to 15G range at standard adult length. Dense or previously irradiated bone requires 11G. Substantial adiposity requires longer instruments, with a depth guard. Paediatric work requires 16G to 18G at short lengths, with tibial access in infancy. These are not opinions; they follow from cortical thickness, soft tissue depth, and bone size.

Indication sets the configuration. Aspiration-only procedures are served by simple needles; procedures requiring histology need trephine or combined instruments; combined designs reduce punctures and should be the network default where both specimens are routinely required.

Material and finish set the performance floor. Stainless steel 304 is adequate for controlled single-use supply in temperate distribution; stainless steel 316 or 316L is preferable where shelf life, climate, or reprocessing stress corrosion resistance. Electropolishing is a functional requirement at every size, and most critically at the fine end.

Packaging and documentation complete the standard: bevel-protective internal fixturing, cartons configured for the network's logistics, and lot traceability to forming and polishing batches.

Running the Standardisation

Begin with data, not with a meeting. Collect twelve months of usage by size and site, and pair it with whatever procedural data exists: repeat rates, specimen adequacy comments, and any recorded complaints. Most networks discover that two or three sizes carry the majority of demand and that the outliers are historical rather than clinical.

Then run a clinical review with representation from each site. The purpose is not to defend current practice but to establish indications. For each size, ask: which patients, which site, which indication, and what evidence supports it. Document the answers. Where sites disagree, the disagreement usually resolves once the underlying anatomy is discussed.

Define the core matrix: the sizes held at every site, with minimum stock levels. Define the extended matrix: sizes held at regional hubs and available within a stated timeframe. Define the exception process: how a site obtains a size outside the matrix, and how such requests are reviewed.

Then align the commercial arrangements. Consolidating to a smaller size set gives the network volume leverage; use it to secure better documentation, custom packaging, and consistent quality rather than only a lower unit price. A supplier selected on price alone will deliver a catalogue that meets the letter of the contract and varies in performance across the range.

Finally, embed the matrix in practice. Post it in procedure rooms. Include it in induction for new clinicians. Add size and lot to the procedure record so that the matrix can be audited rather than assumed.

What Networks Learn in the First Year

Four findings recur.

Consumption rarely reflects indication. Sites that order predominantly 15G often serve similar patient populations to sites ordering 13G, and the difference traces to the preference of a senior clinician who trained elsewhere. Standardisation corrects this quietly and without controversy once the data is visible.

Stock-outs are a matrix problem. A site running out of 11G while holding excess 18G does not need a bigger store room; it needs a matrix matched to its case mix.

Custom sizes multiply without control. Each site orders its own special length, each order is small, and none receives the inspection rigour of catalogue items. Networks that centralise custom orders find they can consolidate to one or two genuinely needed dimensions.

Complaint patterns differ by size, not by site. When complaints are aggregated across the network and tagged by size and lot, the signal emerges clearly: fine gauges generate obstruction complaints, long instruments generate over-advancement reports, and both point to specification issues rather than to individual clinicians.

Standardisation as Quality Assurance

A network matrix is more than a purchasing document. It is the mechanism by which procedure quality becomes comparable across sites, and it is the precondition for any meaningful benchmark - repeat rates, specimen adequacy, procedure time, or pain scores.

Without it, comparisons are invalid: a site with better specimen adequacy may simply be using larger needles. With it, differences reflect practice, and practice can be improved.

A note on transition. Moving a site from its historical practice to the network matrix will produce a transient rise in reported difficulty, because clinicians are using an unfamiliar size for a familiar procedure. Plan for it. Introduce the matrix with the data behind it, allow a defined familiarisation period, and audit during that period rather than after it. Most objections dissolve once the first quarter's repeat rates are compared against the baseline.

There is also a governance question that networks often defer and later regret: who owns the matrix. Assign it explicitly, usually to a clinical supplies committee with representation from haematology, pathology, and infection prevention. An unowned matrix drifts as individual sites reorder their old preferences, and within two years the network is back to twelve opinions with a single contract. Define the owner, define the review date, and write both into the contract cycle so that the matrix is maintained as deliberately as it was built.

Outlook and Recommendations

Consolidation will continue, driven by cost and by regulatory demands for traceability. Expect networks to require lot-level records, defined patency limits, and change notification as standard contractual terms, and expect size matrices to become part of accreditation documentation rather than an internal convenience.

Five recommendations follow. Build the matrix from usage data and anatomical reasoning. Separate core from extended stock with defined replenishment times. Centralise custom orders. Attach documentation and quality requirements to the tender, not only price. And audit the matrix annually, because case mix shifts and yesterday's fit becomes today's stock-out.

A standardised size set is not a restriction on clinical judgement. It is the baseline from which judgement starts, applied consistently to every patient who walks into any site in the network.